This work describes the sub-acute treatment of male Wistar rats with estradiol (E2) and the
17ß-aminoestrogen pentolame (AEP) on the hemostatic screening tests: blood clotting time …

OBJECTIVE To evaluate antithrombin III (AT), thrombin (Fragment 1+ 2 [F1+ 2] and thrombin-
antithrombin [TAT]) generation markers, as well as other coagulation parameters, such as …

Background: Oral estrogen use is associated with changes in plasma levels of many
coagulation proteins. Objective: To gain more insight into the underlying mechanism of …

OBJECTIVE: In this study, we evaluated hemostatic factors related to cardiovascular disease
in postmenopausal women receiving estrogen or combined progestogen replacement …

Objective The effect of hormone replacement therapy (HRT) on coagulation factors and
fibrinolytic components in postmenopausal women was studied for 6 months to elucidate …

INTRODUCTION: Both oestrogen and progestin and the route of administration have been
implicated in cardiovascular and thromboembolic risk in post menopausal hormone users …

The effects of oral and transdermal administration of estrogen replacement therapy (ERT)
have been fairly well investigated regarding lipoprotein and carbohydrate metabolism, while …

Abstract Background/Aims: Hormone replacement therapy (HRT) is associated with an
increased risk of thromboembolism dependent on the type of HRT; therefore, we compared …

Background & Objectives: To assess the effects of different hormone treatment regimes on
blood lipids, lipoproteins, ATIII, fibrinogen in postmenopausal patients. Methods: We studied …

We studied the effects on plasma levels of coagulation and fibrinolysis factors of two
currently used" sub-50" oral contraceptive preparations (OCs), one containing 750 …